This is the authors' abstract. We don't add key points for this paper.
No current treatment options were successful in containing the ongoing pandemic COVID-19 caused by SARS-CoV-2. It is essential to understand the molecular players of SARS-CoV-2 to find a suitable treatment method and to develop an effective antiviral drug as early as possible. Global researchers have undertaken accelerated structural studies of key proteins involved in host-virus interaction, replication, and transcription. In silico studies support structural biologist with preliminary information to efficiently drive further studies and characterization. From the genome sequence, most SARS-CoV-2 annotated ORF has conserved sequence similar to SARS-CoV-1, except for ORF8 and ORF10. The function of ORF8 protein in SARS-CoV-2 is uncertain. Herein, we had modelled the ORF8 protein and studied its putative function using various substrates as probe to determine its biological significance. The modelled SARS-CoV-2 (mORF87A) protein shows IgG characteristic folds and thus may belong to IgG superfamily. Further, we studied the binding efficacy of various antiviral drugs against the modelled ORF8 of SARS-CoV-2 (mORF8) to repurpose the drug and to use them as a probe to study its function by studying the binding/active sites interaction. Remdesivir had the highest binding affinity to ORF8 protein of SARS-CoV-2. The high affinity of the adenosine analogue yields critical information about the non-canonical RNA dependent RNA polymerase (RdRp) function of ORF8 protein. We hypothesize that the ORF8 protein may be a non-canonical RdRp in SARS-CoV-2 with ability to bind to canonical nsp12 complex.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ramya et al. (2020) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: